- Home
- ROOT vs TVTX Comparison
ROOT vs TVTX Comparison
Compare ROOT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- TVTX
- Stock Information
- Founded
- ROOT 2015
- TVTX 2008
- Country
- ROOT United States
- TVTX United States
- Employees
- ROOT N/A
- TVTX N/A
- Industry
- ROOT Property-Casualty Insurers
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- TVTX Health Care
- Exchange
- ROOT Nasdaq
- TVTX Nasdaq
- Market Cap
- ROOT 2.1B
- TVTX 1.9B
- IPO Year
- ROOT 2020
- TVTX N/A
- Fundamental
- Price
- ROOT $136.93
- TVTX $19.68
- Analyst Decision
- ROOT Buy
- TVTX Strong Buy
- Analyst Count
- ROOT 7
- TVTX 13
- Target Price
- ROOT $87.00
- TVTX $33.17
- AVG Volume (30 Days)
- ROOT 835.8K
- TVTX 1.6M
- Earning Date
- ROOT 04-29-2025
- TVTX 05-05-2025
- Dividend Yield
- ROOT N/A
- TVTX N/A
- EPS Growth
- ROOT N/A
- TVTX N/A
- EPS
- ROOT 1.83
- TVTX N/A
- Revenue
- ROOT $1,176,500,000.00
- TVTX $233,175,000.00
- Revenue This Year
- ROOT $9.56
- TVTX $72.95
- Revenue Next Year
- ROOT $12.72
- TVTX $53.84
- P/E Ratio
- ROOT $74.83
- TVTX N/A
- Revenue Growth
- ROOT 158.57
- TVTX 60.55
- 52 Week Low
- ROOT $34.04
- TVTX $5.12
- 52 Week High
- ROOT $181.14
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- ROOT 48.80
- TVTX 45.64
- Support Level
- ROOT $147.01
- TVTX $20.29
- Resistance Level
- ROOT $181.14
- TVTX $20.98
- Average True Range (ATR)
- ROOT 13.24
- TVTX 0.90
- MACD
- ROOT -1.93
- TVTX 0.07
- Stochastic Oscillator
- ROOT 16.35
- TVTX 54.12
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.